Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer

Inclusion Criteria:

* Subjects enrolled in this study must meet one of the 3 following criteria:

  * Group 1: Healthy individual with no history of cancer or hematuria
  * Group 2: Subject with a diagnosis of localized renal cell carcinoma (by imaging and eventual pathology) scheduled to undergo nephrectomy
  * Group 3: Subject with a diagnosis of metastatic renal cell cancer(by imaging and eventual pathology) who is scheduled to begin a new systemic therapy
* Any type of renal cell carcinoma (RCC); any prior therapy
* Performance status: 0-3
* Leukocytes \>= 3,000/mcL (frequently used - numbers listed are examples, investigator should modify as needed)
* Absolute neutrophil count \>= 1,500/mcL (frequently used - numbers listed are examples, investigator should modify as needed)
* Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

* For normal subject arm: no evidence of cancer or hematuria
* For localized RCC arm: no evidence of metastatic disease, second cancer, prior chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
* For metastatic RCC arm: no evidence of second cancer, prior chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
* For all subjects: uncontrolled intercurrent illness including, but not limited to previous or current history of second malignancy unrelated to renal cell carcinoma; autoimmune disease or immune deficiency, chronic treatment with immunomodulatory therapies (e.g. glucocorticoids); significant trauma, surgery, or infection in the past two weeks or psychiatric illness/social situations that would limit compliance with study requirements